J&J’s Stelara faces continued biosimilar competition, with Q2 revenue falling 43%news2025-07-16T11:40:58+00:00July 16th, 2025|Endpoints News|
AstraZeneca says amyloidosis drug anselamimab failed in Phase 3 trialsnews2025-07-16T11:05:56+00:00July 16th, 2025|Endpoints News|
Debiopharm licenses Repare’s first-in-class cancer drug for $10M upfrontnews2025-07-16T10:50:00+00:00July 16th, 2025|Endpoints News|
About 2.5% of all drug patents cite government funding, new study findsnews2025-07-15T18:31:30+00:00July 15th, 2025|Endpoints News|
FDA questions the return of GSK’s Blenrep in multiple myeloma ahead of adcommnews2025-07-15T17:08:54+00:00July 15th, 2025|Endpoints News|
Updated: Hengrui plans China filing for obesity shot following pivotal successnews2025-07-15T11:30:39+00:00July 15th, 2025|Endpoints News|
#IAS25: WHO adds Gilead’s twice-yearly injection to global PrEP guidelinesnews2025-07-14T13:52:40+00:00July 14th, 2025|Endpoints News|
#IAS25: Merck sends new monthly oral PrEP to Phase 3 after earlier islatravir setbacknews2025-07-14T13:30:09+00:00July 14th, 2025|Endpoints News|
Takeda’s first-in-class narcolepsy drug succeeds in two registrational studiesnews2025-07-14T11:22:22+00:00July 14th, 2025|Endpoints News|
AstraZeneca blood pressure pill succeeds in pivotal trial, validating CinCor dealnews2025-07-14T11:18:46+00:00July 14th, 2025|Endpoints News|
